Antibody-Drug Conjugates for the Treatment of Neoplastic Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 2934
Special Issue Editor
Interests: immunotherapy; acute leukemias; stem cell transplantation; lymphomas
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADG) are monoclonal antibodies (Mab) conjugated to cytotoxic agents. The antibody is specific for an antigenic target expressed on the surface of tumor cells. A specific linker is used for conjugation of a cytotoxic agent to the antibody. Following binding of thr antibody to the target, the antibody/antigen complex is internalized, and the cytotoxic agent is released in the cytoplasm, enters the nucleus, and induces DNA damage, finally leading to tumor cell apoptosis. ADGs serve as vehicles for the specific delivery of cell poisons to tumor, while normal cells are spared, thus avoiding significant off-target side-effects. Substantial advances in bioengineering technology have resulted in regulatory approval of several ADGs, such as Trastuzumab–emtansine, Brentuximab–vedotin, Gemtuzumab–ozogamycin, and Inotuzumab ozogamycin for the treatment of breast cancer, Hodgkin’s lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia, respectively, while a few other promising ADGs are now in late-phase clinical testing. The scope of this issue is the review of the mechanism of action, the clinical efficacy, as well as the ongoing efforts focused on identifying better targets, more effective cytotoxic poisons, and more stable antibody–drub binding. Improved understanding of the mechanistic basis of ADGs will enable the design of more effective and safe administration of these antibodies either as monotherapy or in combination with other agents, including immunotherapy.
Dr. Panagiotis Tsirigotis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Antibody-drug conjugates
- Leukemia
- Lymphoma
- Breast cancer
- Solid tumors
